ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KYTX vs XFOR // RETURN ON INVESTED CAPITAL (ROIC)

Kyverna Therapeutics Inc. (NASDAQ) VS. X4 Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: KYTX 1 — XFOR 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYTX VS. XFOR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KYTX XFOR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 83.60% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.8 60.1 -18.30 XFOR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $350.7M $332.1M $18.5M KYTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KYTX REV XFOR REV KYTX GROSS % XFOR GROSS % KYTX FCF XFOR FCF
FY 2025 $475.5M $35.1M — 83.6% -$153.7M -$85.6M
FY 2024 $399.3M $2.6M — 68.8% -$116.5M -$131.2M
FY 2023 $174.7M $301.1M — — -$52.4M -$96.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYTX // BETA —
XFOR // BETA —